Results 131 to 140 of about 29,271 (207)

Brute force: the effects of ibrutinib on brexu-cel. [PDF]

Blood Adv
Peterson CE, Betts BC.
europepmc   +1 more source

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma. [PDF]

Blood Adv
Phillips T, Di M, Miller TA, Wang J, Pierre A, Maglinte GA, Seymour EK, Wang Y.   +7 more
europepmc   +1 more source

High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax. [PDF]

J Med Cases
Gutierrez CLD, Quero-Taggaoa AKH, Uy TCF, Veloso JAD.   +3 more
europepmc   +1 more source

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. [PDF]

, 2018
Bence-Bruckler, I.,, Caballero, D.,, Cho, S. G.,, Dreyling, M.,, Goldberg, J.,, Henninger, T.,, Hess, G.,, Jerkeman, M.,, Joao, C.,, Jurczak, W.,, Lund University., Offner, F.,, Rule, S.,, Rusconi, C.,, Thieblemont, C.,, Trneny, M.,, Vermeulen, J.,, Witzens-Harig, M.,, Zhou, W.,   +18 more
core   +3 more sources

Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. [PDF]

Blood Adv
Darnell EP, Gallagher KME, Kanska J, Scarfò I, Balderrama-Gutierrez G, Berger TR, Budka J, Bozym DJ, Huang T, Shen R, Leick MB, Maus MV.   +11 more
europepmc   +1 more source

Cutaneous Adverse Effects in Patients Treated with BTK Inhibitors. [PDF]

Cancers (Basel)
Robak E, Robak T.
europepmc   +1 more source

Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement [PDF]

, 2017
Doorduijn, J.K. (Jeanette), Hiemcke-Jiwa, L.S. (Laura S.), Huibers, M.M.H. (Manon M. H.), Leguit, P. (Piet), Minnema, M.C. (Monique), Radersma-van Loon, J.H. (Joyce H.), Rood, J.J.M. (Johannes J. M.), Westerweel, J. (Jerry)   +7 more
core   +2 more sources

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort. [PDF]

Blood Adv
Martino EA, Pitino A, Vigna E, Pasquale R, Ferrarini I, Moia R, Visentin A, Sanna A, Motta M, Moratti M, Sportoletti P, Chiarenza A, Maggi A, Zammit V, Merli M, Innocenti I, Giordano C, Nocilli L, Postorino M, Stelitano C, Ferrario A, Frustaci AM, Riva M, Pepe S, Ibatici A, Scardino S, Anticoli Borza P, Ballotta L, Mancuso S, Malaspina F, Mele A, Galimberti S, Catania G, Giordano A, Angeletti I, Schiattone L, Pennese E, Miccolis R, Fama A, Giordano G, Califano C, Bruzzese A, Caserta S, Farina G, Bulian P, Loseto G, Pocali B, Innao V, Galieni P, Fraticelli V, Vitale C, Romeo A, Rossi M, Scortechini I, Vozella F, Malandruccolo L, Varettoni M, Morello L, Pietrantuono G, Conte E, Cantelli M, Murru R, Caracciolo D, Derenzini E, Di Martina V, Marasca R, Del Principe MI, Figuera A, Angotzi F, Coscia M, Di Renzo N, Laurenti L, Amodio N, Musto P, Di Raimondo F, Liso A, Tedeschi A, Trentin L, Gaidano G, Mauro FR, Tripepi G, Morabito F, Gattei V, Gentile M.   +83 more
europepmc   +1 more source

Mechanisms of resistance to bruton's tyrosine kinase inhibitors: synergistic effects of tumor microenvironment regulation and signaling pathways. [PDF]

Ann Hematol
Dong X, Tang S, Chen M, Chen Q, Wang Y, Shi Y, Deng Y, Chen Y, He Z, Yu L, Wang C.   +10 more
europepmc   +1 more source

Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]

Front Oncol
Oura M, Toho M, Ikeda D, Fukuda N, Torres AS, Fujii F, Sakuma H, Uehara A, Tabata R, Narita K, Takeuchi M, Matsue K.   +11 more
europepmc   +1 more source